Vaccines for children in rich and poor countries

Lancet

Volumn 354, Issue SUPPL.2, 1999, Pages

  Shann, Frank ^a   Steinhoff, Mark C ^b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MEASLES VACCINE; MUMPS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; VACCINE; YELLOW FEVER VACCINE;

CHICKENPOX; CHILD; DEVELOPING COUNTRY; HAEMOPHILUS; HEALTH CARE COST; HEPATITIS B; HUMAN; IMMUNIZATION; INFECTION; MEASLES; NEISSERIA MENINGITIDIS; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; RUBELLA; STREPTOCOCCUS PNEUMONIAE; TUBERCULOSIS;

EID: 0032844198     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)90250-7     Document Type: Article

References (38)

1. World Health Organization. The world health report 1998. Geneva: WHO, 1998: 62.
2. UNICEF. The state of the world's children 1999. Oxford: OUP, 1999.
3. OECD. Development co-operation report 1998. Paris: OECD, 1999.
4. Shann F. Pneumococcal vaccine: time for another controlled trial. Lancet 1998; 351: 1600-01.
5. Plotkin SA, Orenstein WA. Vaccines. Philadelphia: Saunders, 1999: 1013.
6. World Health Organization. Vaccine research and development: report of the technical review group meeting, June 9-10, 1997 (WHO/VRD/GEN/97.01). Geneva: WHO, 1997: 32-36.
7. Kayhty H, Eskola J. New vaccines for the prevention of pneumococal infections. Emerg Infect Dis 1996; 2: 289-98.
8. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of the northern California Kaiser Permanente efficacy trial. Presented at APS SPR meeting, May 4, 1999, San Francisco; abstr 941.
9. Invasive Bacterial Infection Surveillance Group (IBIS), International Clinical Epidemiology Network (INCLEN). Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Lancet 1999; 353: 1216-21.
10. World Health Organization. Report on the meeting on maternal and neonatal pneumococcal immunization, Geneva, Jan 26-27, 1998 (WHO/VRD/GEN/98.01). Geneva: WHO, 1998.
11. Aaby P, Anderson M, Sodermann M, Jakobsen M, Gomes J, Fernandes M. Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age. BMJ 1993; 307: 1308-11.
12. Aaby P, Samb B, Simondon F, Coll Seek AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ 1995; 311: 481-85.
13. Shann F. A little bit of measles does you good. BMJ 1999; 319: 4-5.
14. Cutts F, Steinglass R. Should measles be eradicated? BMJ 1998; 316: 765-67.
15. Steinhoff MC. Haemophilus influenzae type b infections are preventable everywhere. Lancet 1997; 349: 1186-87.
16. Shann F, Germer S, Hazlett D, Gratten M, Linnemann V, Payne R. Aetiology of pneumonia in children in Goroka Hospital, Papua New Guinea. Lancet 1984; ii: 537-41.
17. Wall RA, Mabey DCW, Corrah PT. Haemophilus influenzae non type b. Lancet 1985; ii: 845.
18. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349: 1191-97.
19. Cunliffe NA, Kilgore PE, Bresee JS, Steele AD, Luo N, Hart CA, Glass RI. Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull WHO 1998; 76: 525-37.
20. Perez-Schael I, Guntinas MJ, Perez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337: 1181-87.
21. Lanata CF, Midthun K, Black RE, et al. Safety, immunogenicity and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996; 174: 268-75.
22. Linhares AC, Gabbay YB, Mascarenhas JDP, et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull WHO 1996; 74: 491-500.
23. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. Pediatrics 1996; 97: 7-13.
24. Elliman D. Whooping cough vaccines: where next? Child Care Health Develop 1998; 24: 259-65.
25. Gangarosa EJ, Galezka AM, Wolfe CR, Phillips LM, Gangarosa RE, Miller E, Chen RT. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998; 351: 356-61.
26. Cohn DL. Use of the Gacille Calmette-Guérin vaccination for the prevention of tuberculosis: renewed interest in an old vaccine. Am J Med Sci 1997; 313: 372-76.
27. Lowrie DB, Silva CL, Tascon RE. Genetic vaccination against tuberculosis. Springer Semin Immunopathol 1997; 19: 161-73.
28. Hasley NA, Duclos P, Van Damme P, Margolis H. Hepatitis B vaccine and central nervous system demyelinating diseases (Viral Hepatitis Prevention Board). Pediatr Infect Dis J 1999; 18: 23-24.
29. Peltola H. Meningococcal vaccines. Drugs 1998; 55: 347-66.
30. Robbins JB, Towne DW, Gotschlich EC, Schneerson R. "Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet 1997; 350: 880-82.
31. White CJ. Varicella-zoster virus vaccine. Clin Infect Dis 1997; 24: 753-63.
32. Cutts FT, Robertson SE, Diaz JL, Samuel R. Control of rubella and congenital rubella syndrome in developing countries. Bull WHO 1997; 75: 55-68.
33. Miller LH, Hoffman SL. Research toward vaccines against malaria. Nat Med 1998; 4 (suppl): 520-24.
34. UNAIDS, World Health Organization. AIDS epidemic update: December 1998. Geneva: UNAIDS, 1998.
35. LaCasse RA, Follis K, Trahey M, Scarboborough JD, Littman DR, Nunberg JH. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 1999; 283: 357-62.
36. Crowe JE. Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines. Vaccine 1998; 16: 1423-32.
37. Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998; 11: 430-39.
38. Stratton KR, Durch JS, Lawrence RS, eds; Committee to Study Priorities for Vaccine Development. Vaccines for the 21st century: a tool for decisionmaking. Washington, DC: Institute of Medicine, 1999.